Stocks and Investing
Stocks and Investing
Mon, June 14, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sun, June 13, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, June 11, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (VRTX) at Hold with Decreased Target to $205 on, Jun 11th, 2021
Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Decreased Target from $254 to $205 on, Jun 11th, 2021.
Matthew has made no other calls on VRTX in the last 4 months.
There are 2 other peers that have a rating on VRTX. Out of the 2 peers that are also analyzing VRTX, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Matthew
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $279 on, Wednesday, May 12th, 2021
- Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $260 on, Monday, May 3rd, 2021
Contributing Sources